Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
Novartis joins seven global companies to found the Value Balancing Alliance
Novartis announced the company’s financial results for the second quarter and first half of 2019.
Novartis transforms its Global Health & Corporate Responsibility organization.
For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment.
Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.
Novartis announced the company’s financial results for the first quarter of 2019.
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.